Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101
Last updated 2026-05-18
Summary
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.
Conditions
- Anal Melanoma
- Bladder Melanoma
- Cervical Melanoma
- Esophageal Melanoma
- Gallbladder Melanoma
- Head and Neck Mucosal Melanoma
- Mucosal Melanoma
- Nasopharyngeal Mucosal Melanoma
- Oral Cavity Mucosal Melanoma
- Penile Mucosal Melanoma
- Rectal Melanoma
- Recurrent Mucosal Melanoma
- Sinonasal Mucosal Melanoma
- Urethral Melanoma
- Urinary System Mucosal Melanoma
- Vaginal Melanoma
- Vulvar Melanoma
Interventions
- PROCEDURE
-
Biospecimen Collection
Undergo blood and tissue sample collection
- PROCEDURE
-
Bone Scan
Undergo bone scan
- DRUG
-
Cabozantinib S-malate
Given PO
- PROCEDURE
-
Computed Tomography
Undergo CT
- PROCEDURE
-
Echocardiography Test
Undergo ECHO
- PROCEDURE
-
Magnetic Resonance Imaging
Undergo MRI
- BIOLOGICAL
-
Given IV
- DRUG
-
Placebo Administration
Given PO
- PROCEDURE
-
Positron Emission Tomography
Undergo PET
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Alexander N Shoushtari · Alliance for Clinical Trials in Oncology
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-08-11
- Primary Completion
- 2026-09-01
- Completion
- 2026-09-01
- FDA Drug
- Yes
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
NCT01176474 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
NCT01585194 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
NCT05041062 ·Status: COMPLETED ·Phase: PHASE2
-
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196 ·Status: RECRUITING ·Phase: PHASE2
-
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
NCT03033576 ·Status: COMPLETED ·Phase: PHASE2
-
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT02684253 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
NCT02832167 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
NCT00085189 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
NCT02304458 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
NCT00059475 ·Status: COMPLETED ·Phase: PHASE2
-
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
NCT03012581 ·Status: COMPLETED ·Phase: PHASE2
-
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
NCT05629546 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
NCT04521075 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
NCT06151847 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
NCT04957615 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
NCT02720484 ·Status: TERMINATED ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT00006347 ·Status: UNKNOWN ·Phase: PHASE1
-
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT05647265 ·Status: RECRUITING ·Phase: PHASE2
-
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
NCT04847466 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
NCT01993719 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
NCT02339558 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
NCT01026051 ·Status: TERMINATED ·Phase: PHASE2
-
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT04013854 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
NCT04940299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2